Evidence map›Paper›PMID 42204266›Full record

ArticleOncogene2026

MST4 plays dual roles in lung adenocarcinoma by regulating homeostasis of wild-type and mutant p53 protein.

Minghui Zhang, Changwei Hu, Huilong Liu, Chenxi Zhang, Qipeng Shu, Yu-Jian Kang, Yuetian Ding, Jin Zhang, Zhenghui Hu, Haokai Wang and 3 more

Abstract read
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Minghui Zhang *Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, PR China. zhangminghui160@163.com.
Changwei Hu *School of Medicine, Chongqing University, Chongqing, PR China.ORCID http://orcid.org/0009-0003-1539-2107
Huilong Liu *School of Medicine, Chongqing University, Chongqing, PR China.
Chenxi ZhangSchool of Medicine, Chongqing University, Chongqing, PR China.
Qipeng ShuSchool of Medicine, Chongqing University, Chongqing, PR China.
Yu-Jian KangSchool of Medicine, Chongqing University, Chongqing, PR China.
Yuetian DingCollege of Medicine, Tibet University, Lhasa, PR China.
Jin ZhangSchool of Medicine, Chongqing University, Chongqing, PR China.
Zhenghui HuThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences and Institute of Biomedical Innovation, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
Haokai WangThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences and Institute of Biomedical Innovation, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
Youfan ZhangSchool of Medicine, Chongqing University, Chongqing, PR China.
Ze-Yan ZhangThe MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences and Institute of Biomedical Innovation, Jiangxi Medical College, Nanchang University, Nanchang, PR China. zhangzeyan@ncu.edu.cn.ORCID http://orcid.org/0000-0002-7896-3013
Shangze LiSchool of Medicine, Chongqing University, Chongqing, PR China. shangze.li@cqu.edu.cn.ORCID http://orcid.org/0000-0003-3134-532X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations are highly prevalent in the TP53 tumor suppressor gene, which encodes p53, in lung adenocarcinoma (LUAD). However, targeted therapies centered on p53 mutations remain challenging. Here, we found MST4 highly expressed in LUAD and linked to patient survival. Functional assays using CRISPR-generated MST4-knockout LUAD cell lines revealed context-dependent dual roles of MST4: tumor-suppressive in wild-type p53 (wtp53) cells (inhibiting proliferation, colony formation, migration) and oncogenic in gain-of-function (GOF) p53 cells. Mechanistically, MST4 directly interacts with p53, competing with MDM2 to prevent K48-linked ubiquitination and degradation of both wtp53 and GOF-mutant p53, which explains cell-context-dependent phenotypes of MST4 suppression. Preclinically, targeting MST4 significantly repressed tumor formation of xenograft model with GOF-mutant p53. Collectively, our findings identify MST4 as a context-dependent regulator of LUAD, whose function is dictated by p53 mutation status. MST4 stabilizes p53 via a novel MDM2-competitive, kinase-independent mechanism, and targeting MST4 represents a promising therapeutic strategy for GOF-mutant p53-driven LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsProtein Serine-Threonine KinasesTumor Suppressor Protein p53AnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHippo KinasesHomeostasisHumansIntracellular Signaling Peptides and ProteinsMiceMutationProto-Oncogene Proteins c-mdm2UbiquitinationHippo KinasesIntracellular Signaling Peptides and ProteinsMDM2 protein, humanProtein Serine-Threonine KinasesProto-Oncogene Proteins c-mdm2STK4 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID42204266
PMCPMC13286987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.